Navigation Links
University of Leicester to lead audit of adults with autism
Date:5/9/2008

The University of Leicester is leading on a national study to calculate the number of adults with autism, it has been announced today.

Professor Terry Brugha, Professor of Psychiatry in the Department of Health Sciences is spearheading the study in conjunction with a team of research experts including the the National Centre for Social Research (NatCen), Research Autism and Professor Simon Baron-Cohen of the Autism Research Centre. It will report in 2009.

Care services Minister Ivan Lewis announced an additional investment of 500,000 for Government research into the numbers of adults with autism and their specific transitions needs. This prevalence study will inform the first ever Government strategy on adults with autism and Asperger's syndrome.

The number of children with autism is as high as 1 in 100 (according to studies by Prof Howard Meltzer of the University of Leicester and Prof. Baird's 2006 study). The new prevalence study now underway will give the first ever accurate picture of how many adults have the condition. Part of the new research will focus on the period of transition to adult life and will inform service planning for adults with Autistic Spectrum Disorders (ASDs). This will be led by Prof. Baird and it will examine the lessons and challenges in the transition process and focus on areas such as mental health, social care, housing and further education needs.

Professor Brugha is Director of Research, Department of Health Sciences, University of Leicester and Honorary Consultant Adult General Psychiatrist, Leicestershire Partnership NHS Trust. He operates an NHS assessment clinic for adults who may have Autism Spectrum Disorder and liaise with adult mental health services throughout Leicester and Leicestershire, also providing training to professional staff and teams.

His area of research is psychiatric epidemiology in adulthood. He is also currently developing and testing methods for the prevent
'/>"/>

Contact: Professor Brugha
01-162-584-395
University of Leicester
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. University of Iowa professor identifies new eating disorder
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
4. Tulane University to receive $14M for international HIV/AIDS program
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. Boston University School of Medicine researcher recipient of Memory Ride Grant
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
9. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ANTON, Calif., July 25 /PRNewswire-FirstCall/ -- T...r in device-based mechanical,circulatory support t...ts,today announced that it will report its operat...onths of fiscal 2008 on Thursday, July 31., The c...financial,results and operating activities to all ...
(Date:7/25/2008)...rtain cleaning products reduces lung function, inc... FRIDAY, July 25 (HealthDay News) -- A clean, fres...h, depending on what type of cleaning and air fres...ests that exposure to cleaning products or air fre...mpound (VOC) called 1,4 dicholorobenzene (1,4 DCB)...
(Date:7/25/2008)...OK, Ill. July 25, 2008 The American Society for...elines on the role of endoscopy in the bariatric s...n the United States and the success in surgical in... of weight-loss surgeries performed in the U.S., f...nes discuss endoscopy in the preoperative patient ...
(Date:7/25/2008)...S, July 25 /PRNewswire/ -- BeaconEquity.com announ...ing news today., Investors can view all of the da...aconEquity.com/m , Today,s Trade Alerts include: ...Brook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaM...R ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis I...
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...lic supplements may not help reduce cholesterol or...lic consumed, says a new study//. Several earlier...ower cholesterol. However, researchers at Stanford...different garlic supplements on nearly 200 adults ...
...vehicles whiz past E.M. Bypass on the city's easte...left indicates the Kolkata Municipal Corporation's... Animals (PFA). It is here that the adage every ...ling pound aims to restore the mental and physical...
...earchers in Philadelphia have found a ground break...brought them to be able to trigger the Epstein-Bar...ntify patients whose infections can then be manipu...at this strategy could actually offer a novel way ...
... annual report for the year 2006 of the Internatio...to UN), suggests that abuse of prescriptions drugs...obe. The abuse of prescription drugs surpasses ...asy, cocaine and heroine in parts of Europe, Afric...
Other Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 2Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 3
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: